← Home

Blog

Articles about AI search, verification, and platform updates

AI News: The Day's Highlights

June 8, 2026 · 4 min read

Perplexity

The most significant recent news is not about a specific AI tool, but about a shift in regulation: in March 2026, the Ministry of Digital Development put forward a draft law for discussion with unified rules for the development and application of AI in Russia, including healthcare. The document introduces a risk-based approach and the concept of "trusted models," which, after verification, can be used in the public sector and critical infrastructure, including medicine.[2][5]

This is important for medicine and biotech because such a regime can accelerate the adoption of AI in clinical practice and reduce legal uncertainty for developers and hospitals. Against the backdrop of the already noticeable increase in AI use by doctors and the expansion of clinical scenarios, this appears to be a more significant turning point than another private case of diagnostics or drug development.[2]

Sources:

  • Vademecum, "AI in Healthcare. Vademecum Digest for March 15-21, 2026."
  • "Expert," "How Russia Will Regulate AI in Healthcare."

Gemini

The application of AI for deciphering medical analyses is actively developing in Russia. Residents of the Moscow region are already using an artificial intelligence-based service, with approximately 62,000 people connected to it. It is important to note that the results of the deciphering are purely advisory.

In the field of biotechnology, there is a transition from the development of basic models to the "clinical era," where AI-developed drugs are undergoing clinical trials. It is expected that in 2026, several such candidates will reach critical research stages. Companies such as Iambic and Generate plan to have more than three AI-developed drugs in clinical trials.

Furthermore, AI is increasingly being used for analyzing medical images, processing electronic health record data, and supporting medical decision-making. This allows for the automation of routine processes, reduces the workload on specialists, and improves the accuracy of data interpretation. In the future, AI may become an important tool for telemedicine, providing remote patient monitoring and decision support.

Sources:

  • Artificial intelligence will replace some diagnostic doctors in 3-5 years (PharmMedProm)
  • AI has begun to be used for deciphering medical analyses in the Moscow region (NEWS.ru)
  • The Latest AI News + Breakthroughs in Healthcare and Medical (Google AI Blog)
  • The Clinic of the Future: AI Application Today (Siberian.pro)

ChatGPT

In April 2026, the role of artificial intelligence (AI) in pharmaceuticals and medicine was discussed at the Forum of Future Technologies in Moscow. Experts noted that AI accelerates scientific research by analyzing large datasets and contributing to the creation of new drug forms. In particular, Artur Kadurin, Director of the AI Drug Discovery Center at the Artificial Intelligence Research Institute (AIRI), emphasized that AI not only helps in searching for new molecules but also in generating them, reducing development time to 2-3 years. (vedomosti.ru)

Grok

In early May 2026, IBM Research unveiled MAMMAL – a multimodal foundation model for biomedical discovery. The model is trained on approximately two billion biological samples (protein sequences, small molecules, gene expression profiles) and demonstrates state-of-the-art results in nine out of eleven drug discovery benchmarks, surpassing AlphaFold 3 in several tasks.

The publication in npj Drug Discovery (May 4th) highlights the transition of AI from narrow tools to universal systems that simultaneously work with genes, proteins, and chemical compounds. This paves the way for accelerated molecule design and more accurate prediction of their interactions with biological targets.

The event is dated May 4, 2026. Such models are already being tested in real-world drug discovery tasks, where they reduce the time from idea to drug candidates.

Sources:

Claude

Here is the most significant breaking news:

On January 7, 2026, Insilico Medicine, a company entirely built on AI drug discovery, announced a partnership with the French company Servier worth up to $888 million – just a week after its historic IPO in Hong Kong, when its shares soared 25% on the first day of trading.

This event is a turning point for the entire industry. Eli Lilly and other major pharmaceutical companies have already invested in AI drug discovery – Eli Lilly signed a deal worth over